Other than the Topline data for the ATH434-202 Advanced study due in Q2, there will not be any new info to give the share price a kick along any time soon. They have a planned meeting with FDA re the phase 2 study in Q4 this year. Was hoping for an earlier date. So I assume we cannot expect any accelerated approval before next year. Lets hope that the topline data for the 202 is spectacular which may move the SP up.
Other than the Topline data for the ATH434-202 Advanced study...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $12.66K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4352071 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 8220041 | 19 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |